ASCO 2018 Review

HR+/HER2- Therapies Take The Stage:  With ASCO 2018 now behind us, we have time to reflect on the advances and challenges that remain for patients with metastatic breast cancer (mBCa).  Hormone receptor positive (HR+) (mBCa) was a key focus area for this year’s meeting.  Key takeaways and analysis of selected HR+ mBCa data are presented in this blog post.

Read More